Compare KALA & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | TCMD |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 300.1M |
| IPO Year | 2017 | 2016 |
| Metric | KALA | TCMD |
|---|---|---|
| Price | $0.36 | $27.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $31.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 731.1K | 400.5K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.50 | 17.14 |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.60 |
| Revenue Next Year | N/A | $9.14 |
| P/E Ratio | ★ N/A | $34.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $8.61 |
| 52 Week High | $20.58 | $37.77 |
| Indicator | KALA | TCMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 44.63 |
| Support Level | $0.35 | $26.47 |
| Resistance Level | $0.72 | $30.74 |
| Average True Range (ATR) | 0.05 | 1.18 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 70.79 | 26.35 |
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.